|
|
||||||||
Laboratoire dImmunopharmacologie, Institut National de la Santé et de la Recherche Médicale, Unité 503, Centre dEtudes et de Recherche en Virologie et Immunologie, Lyon, France
| Abstract |
|---|
|
|
|---|

m)
disruption. In contrast, etoposide (ETO), staurosporine (STS), or IL-2
withdrawal triggers concomitant caspase activation, PS exposure, and

m disruption. Such kinetics suggest that PS exposure could be
independent of caspase activation. As expected, in activated PBL
treated by anti-CD95 mAb, the pan-caspase inhibitor
Cbz-Val-Ala-Asp(OMe)-fluoromethylketone and the caspase-8 inhibitor
Cbz-Leu-Glu-Thr-Asp(OMe)-fluoromethylketone, but not the caspase-9
inhibitor Cbz-Leu-Glu-His-Asp(OMe)-fluoromethylketone, inhibit PS
externalization and 
m disruption. Surprisingly, during apoptosis
induced by ETO, STS, or IL-2 withdrawal, none of those caspase
inhibitors prevents PS externalization or 
m disruption, whereas
they all inhibit DNA fragmentation as well as the morphological
features of nuclear apoptosis. In Jurkat and H9 T cell lines, as
opposed to activated PBL, PS exposure is inhibited by
Cbz-Val-Ala-Asp(OMe)-fluoromethylketone during apoptosis induced by
CD95 engagement, ETO, or STS. Thus, caspase-independent PS exposure
occurs in primary T cells during apoptosis induced by stimuli that do
not trigger death receptors. | Introduction |
|---|
|
|
|---|
, IL-10, and PGE2,
clearance of apoptotic cells also sets up an anti-inflammatory
milieu within the tissue (4).
Many receptors, including C1q and lectin receptors (5),
scavenger receptors such as CD68 (6) or CD36 associated
with
v
3 or
v
5 vitronectin
receptors (7, 8), CD14 (9, 10), and the
recently cloned phosphatidylserine
(PS)4 receptor
(11) have been reported to mediate the binding and uptake
of apoptotic cells by macrophages. The most characteristic surface
change on apoptotic cells is the loss of phospholipid bilayer asymmetry
and the exposure of oxidized PS on the outer leaflet of the plasma
membrane (12, 13, 14, 15, 16), the latter change being absolutely
required for recognition and engulfment to occur (2, 16).
Although the PS receptor specifically recognizes PS exposed on the
surface of apoptotic cells, the milk fat globule-EGF-factor 8, a
secreted glycoprotein produced by activated macrophages, may also bind
to PS, facilitating recognition by
v
3 expressed on
phagocytes (17). While PS is actively transported from the
outer to the inner leaflet of the plasma membrane by ATP-dependent
aminophospholipid translocase (12, 18), the implication of
a scramblase that moves phospholipids bidirectionally across the
membrane is still debated (19).
Proteolytic activity plays an important role in apoptosis, and caspases
appear to be essential for the execution of apoptotic process
(20). Caspases are cysteine proteases, highly conserved
through evolution, that have an absolute specificity for an aspartic
acid in the P1 position of the substrate and
cleave important cellular substrates responsible for characteristic
features of apoptosis (21). Among these substrates,
protein kinase C
, which phosphorylates scramblase 1 during apoptosis
(22), is cleaved by caspase-3, suggesting a plausible
mechanism by which this kinase, and subsequently the scramblase, can
become activated in a sustainable manner. Moreover the pan-caspase
inhibitor Cbz-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD) has been
shown to inhibit PS exposure in cell lines undergoing apoptosis
(23, 24), suggesting that PS externalization is a
caspase-dependent feature of apoptosis. Meanwhile, caspase-independent
PS exposure and specific phagocytic clearance have been reported in
aged platelets (25).
Despite their critical importance to recognition and engulfment of
apoptotic cells, the mechanisms mediating externalization of PS are
still not well defined. In particular, the role of caspases in this
phenomenon is still debated. In the present study we investigated the
implication of caspases in PS exposure and mitochondrial transmembrane
potential (
m) disruption in primary T cells undergoing apoptosis
by physiological stimuli either by IL-2 withdrawal, which mimics death
by neglect when Ag has been cleared from the organism, or by a more
active form involving death receptors, such as CD95 (26).
We also used drugs (etoposide and staurosporine) that are known to
trigger mitochondrial-dependent apoptosis in activated PBL (27, 28). In contrast to T cell lines, PS exposure in primary T cells
undergoing apoptosis by staurosporine (STS), etoposide (ETO), or IL-2
withdrawal is caspase independent. Our results further point to an
intimate association between PS exposure and 
m disruption,
suggesting that mitochondria could control PS exposure.
| Materials and Methods |
|---|
|
|
|---|
PHA, Hoechst 33342, STS, and ETO were purchased from Sigma-Aldrich (St. Quentin Fallavier, France). Recombinant human IL-2 was obtained from Chiron-France (Suresnes, France). The broad spectrum caspase inhibitor benzylloxycarbonyl zVAD was purchased from Bachem (Voisins-Le-Bretonneux, France). The caspase-8 Cbz-Ile-Glu-Thr-Asp(OMe)-fluoromethylketone (zIETD) and the caspase-9 Cbz-Leu-Glu-His-Asp(OMe)-fluoromethylketone (zLEHD) inhibitors were obtained from Calbiochem (Meudon, France). The agonistic anti-CD95 Ab (7C11, IgM) was purchased from Immunotech (Marseilles, France).
Cell preparation and culture
PBL were collected from healthy donors in the presence of sodium citrate. Blood was defibrinated, then mononuclear cells were isolated by centrifugation on a layer of Histopaque (Dutcher, Brumath, France). Those suspensions contained 74.4 ± 2.0% T lymphocytes, 7.5 ± 1.2% B lymphocytes, 16.1 ± 1.9% NK cells, and 0.8 ± 0.4% monocytes as defined by the expression of CD3, CD20, CD56, and CD14, respectively. PBL were resuspended in RPMI 1640 (Sigma-Aldrich) supplemented with 10% FCS, 2 mM L-glutamine, and antibiotics (penicillin, 100 U/ml; streptomycin, 100 µg/ml) and were cultivated in a humid atmosphere containing 5% CO2.
Activated T lymphocytes were obtained by activation of PBL for 3 days with PHA (5 µg/ml). At this stage dead cells were removed, and viable cells (106/ml) were treated with the different apoptotic stimuli in the presence or the absence of caspase inhibitors. After 3 days of stimulation with PHA, cells were further incubated for 7 days with IL-2 (50 U/ml). In these conditions, T lymphoblasts were susceptible to apoptosis induced by IL-2 withdrawal (29).
The human T leukemia cell lines Jurkat and H9 were obtained from American Tissue Culture Collection (Manassas, VA) and provided by Dr. K.-M. Debatin (University Childrens Hospital, Ulm, Germany). Both cell lines were maintained in RPMI 1640 (Sigma-Aldrich) supplemented with 10% FCS, 2 mM L-glutamine, and antibiotics (penicillin, 100 U/ml; streptomycin, 100 µg/ml) and were cultivated in a humid atmosphere containing 5% CO2.
Flow cytometric analysis of different parameters of apoptosis
PS exposure was quantified by surface binding of annexin V (14). Cells (2 x 105) were resuspended in annexin V binding buffer containing FITC-conjugated annexin V for 15 min following the instructions of the manufacturer (Bender MedSystems, Vienna, Austria). Propidium iodide (PI; 1 µg/ml) was then added, and cell suspension was immediately analyzed by flow cytometry using a FACSCalibur and CellQuest software (BD Biosciences, Pont de Claix, France).
Analysis of 
m was determined by incubating cells at 37°C for 15
min with 40 nM of the cationic lipophilic fluorochrome
3,3'-dihexylocarbocyanine iodide (DiOC6;
Molecular Probes, Eugene, OR) (30), followed by immediate
analysis by flow cytometry.
Single-stranded DNA fragmentation was detected using F7-26 mAb from Alexis Corp. (Apostain; Laufelfingen, Switzerland), according to the manufacturers instructions.
Percentages of cells with active caspases were estimated by flow cytometry staining with an in situ marker FITC-VAD-fluoromethylketone (CaspACE) from Promega (Charbonnieres, France) according to the manufacturers protocol.
Western blot
Treated cells were washed with PBS, and pellets were resuspended in lysis buffer (10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Triton X-100, 10 mM EDTA, and the protease inhibitor mixture). Thirty micrograms of proteins were separated on SDS-PAGE and transferred to nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). Blots were blocked for 2 h at room temperature in PBS/0.1% Tween containing 5% nonfat dried milk and incubated overnight at 4°C with anti-caspase-8 (provided by P. Krammer), anti-caspase-3 (BD PharMingen, San Diego, CA), or anti-actin Abs (Sigma-Aldrich). Detection was achieved with the appropriate secondary Abs coupled to HRP (Amersham, Les Ulis, France), followed by ECL Western blotting (Amersham), and autoradiography was performed.
| Results |
|---|
|
|
|---|

m disruption, and PS exposure
during apoptosis of PBL
As a first approach to assess the role of caspases in PS
externalization, the kinetics of caspase activation were compared with
those of 
m disruption and PS externalization in activated PBL
treated with anti-CD95 mAb, STS, or ETO or after withdrawal of
IL-2. Caspase activation was first studied by flow cytometry analysis
using the broad spectrum substrate FITC-VAD-fmk. Anti-CD95 mAb induces
a rapid activation of caspases, detected in 22% of the cells by 3
h and reaching a maximum at 12 h, at which time 36% of the cells
exhibited activation of caspases (Fig. 1
A). STS and ETO induce a
later activation of caspases, since STS-treated cells exhibited
only 15% of cells with active caspases after 3 h, and ETO-treated
cells needed >6 h to exhibit active caspases (Fig. 1
A).
|
|

m disruption and PS externalization were also
studied by cytofluorometric analysis using DiOC6
and annexin V-FITC, respectively. Anti-CD95 mAb and STS induce PS
externalization and 
m disruption starting as early as 3 h
and reaching a plateau after 12 h, whereas 6 h were required
after treatment with ETO (Fig. 1
m disruption showed the same kinetics (Fig. 1
m disruption in
CD95-induced apoptosis, whereas concomitant caspase activation, PS
exposure, and 
m disruption were detected after STS-, ETO-, or
IL-2 withdrawal-induced apoptosis. Such kinetics suggest that in PBL,
PS exposure could be independent of caspase activation after STS-,
ETO-, or IL-2 withdrawal-induced apoptosis.
Caspase inhibitors do not prevent PS exposure and 
m
disruption induced by STS, ETO, or IL-2 withdrawal in PBL
To investigate whether caspases are required for PS
externalization in PBL undergoing apoptosis, we investigated the effect
of caspase inhibitors on PS exposure and 
m disruption. As
expected, in activated PBL treated by anti-CD95 mAb, the
pan-caspase inhibitor zVAD and the caspase-8 inhibitor zIETD inhibited
PS externalization and 
m disruption, whereas the caspase-9
inhibitor zLEHD demonstrated only partial inhibition (Fig. 3
, A and B).
Surprisingly, in cells undergoing apoptosis induced by STS or ETO none
of those caspase inhibitors decreased the percentage of annexin
V-positive cells nor that of low DiOC6 cells
(Fig. 3
, A and B), suggesting that with these
agents PS exposure and 
m disruption were caspase independent.
These observations were confirmed in cells undergoing apoptosis after
IL-2 withdrawal. In those cells PS exposure and 
m disruption were
not inhibited by addition of zVAD (Fig. 3
C).
|
Since zVAD was unable to inhibit plasma membrane and mitochondrial
loss of integrity in PBL undergoing apoptosis induced by STS, ETO, and
IL-2 withdrawal, we investigated whether DNA fragmentation and
morphological features of nuclear apoptosis were caspase dependent.
zVAD inhibited DNA fragmentation whatever the apoptosis-inducing
stimuli, whereas caspase-8 inhibitor only blocked anti-CD95
mAb-induced apoptosis (Fig. 4
, A and B). zLEHD decreased DNA fragmentation of
PBL undergoing apoptosis induced by STS, ETO, and anti-CD95 mAb
(Fig. 4
A), suggesting that caspase-9 may be required with
other caspases to induce DNA fragmentation whatever the
apoptosis-inducing stimuli. The pan-caspase inhibitor zVAD also
inhibited nuclear condensation as well as nuclear fragmentation induced
by STS, ETO, and anti-CD95 in PBL (Fig. 4
C), confirming
the implication of caspases in modeling nuclear apoptosis.
|

m disruption
To determine whether the phenomenon of dissociation of PS exposure
from caspase activation was cell type specific, we extended the study
to the human T cell lines Jurkat and H9. These cells were treated with
the same apoptosis-inducing stimuli, STS, ETO, or anti-CD95 mAb, in
the presence or the absence of the pan-caspase inhibitor zVAD. In
Jurkat and H9 T cell lines, zVAD inhibited PS exposure induced by
anti-CD95 mAb, but, at variance from what is reported above for
PBL, it prevented PS exposure induced by STS and ETO (Fig. 5
A). Similarly, zVAD inhibited

m disruption induced by anti-CD95 mAb as well as by STS and
ETO (Fig. 5
B). Thus, the caspase-independent feature of PS
exposure and 
m disruption is cell type specific and restricted
to PBL.
|
| Discussion |
|---|
|
|
|---|

m disruption. Such kinetics are in agreement with the fact
that proximal signaling from death receptors requires the formation of
a death-inducing signaling complex, in which caspase-8 is rapidly
processed into its active heterotetrameric form (31).
These events occur upstream of the mitochondria and explain the
powerful inhibition of both 
m disruption and PS exposure by the
pan-caspase inhibitor zVAD as well as the caspase-8 inhibitor
zIETD. In contrast, the kinetics of caspase activation, PS
exposure, and 
m disruption in PBL undergoing apoptosis induced by
STS, ETO, or IL-2 withdrawal do not rule out a possible
caspase-independent regulation of PS exposure. This hypothesis was
indeed confirmed by the demonstration that none of the caspase
inhibitors tested was able to inhibit PS exposure and 
m
disruption, whereas zVAD and the caspase-9 inhibitor zLEHD completely
or partially inhibited DNA fragmentation, respectively. These results
suggest that in primary T cells undergoing apoptosis induced by stimuli
that do not involve death receptors, PS exposure and 
m disruption
do not require caspase activation. In keeping with the present data, it
was shown by Verhoven et al. (32) that PS exposure in
D011.10 T cell hybridoma required caspase activation when apoptosis was
triggered by CD95, but not when it was induced by glucocorticoids.
In T cell lines we demonstrate here that zVAD blocks both PS exposure
and 
m disruption whatever the apoptosis-inducing stimulus, in
agreement with previously published results (23, 24, 27).
The discrepancy between primary T cells and T cell lines may reflect a
difference in uncharacterized intracellular esterases, which are
necessary to obtain the active form of caspase inhibitors. However, the
ability of zVAD to inhibit both DNA fragmentation and morphological
changes in nuclear apoptosis of PBL (Fig. 4
) rules out a general
deficiency of esterases in PBL. This discrepancy may also be related to
the fact that in T cell lines cytochrome c can be released
from mitochondria even when 
m is normal (27).
Indeed, the loss in 
m was only observed after activation of a
succinyl-Asp-Glu-Val-Asp-specific caspase(s) (27).
Moreover, the caspase inhibitor zVAD effectively blocked 
m
disruption induced by apoptosis-inducing agents in T cell lines (Fig. 5
), but failed to block the release of cytochrome c
(27). This suggests that in contrast to primary T cells,

m disruption in T cell lines may be a consequence of caspase
activity rather than the effector mechanism driving cytochrome
c efflux.
In primary T cells as well as in T cell lines, no dissociation between

m disruption and PS exposure could be detected in experiments
using caspase inhibitors. It thus appears that these two apoptotic
events are intimately associated and that one of them could be the
consequence of the other. Indeed, one may hypothesize that PS exposure
could be the consequence of an ATP depletion, consecutive to the

m disruption, that would inhibit the activity of the
ATP-dependent aminophospholipid translocase. In accordance with this
hypothesis, 
m disruption precedes PS exposure in thymocytes both
in vitro and in vivo after treatment with the glucocorticoid analog
dexamethasone (33), and 
m disruption is associated
with a rapid cessation of ATP synthesis (34). Furthermore,
oligomycin, an inhibitor of the
F0-F1 ATPase, as well as
inhibitors of the respiratory chain such as antimycin A are rapid
inducers of PS exposure (33, 35). Further evidence for the
role of ATP-dependent aminophospholipid translocase in PS exposure was
recently obtained by experiments involving ATP depletion by
2-deoxyglucose or in glucose-free medium (36) Another
hypothesis would involve the apoptosis-inducing factor (AIF) as a key
protein in the regulation of PS exposure. Indeed, microinjection of AIF
into the cytoplasm of intact cells induces PS exposure, and this effect
is not prevented by zVAD (37), suggesting that AIF induces
caspase-independent PS exposure. AIF would exert this function by
activating the scramblase or by activating a caspase-independent
protease (38) involved in the degradation of fodrin, a
protein associated with the maintenance of membrane lipid asymmetry, by
anchoring PS at the inner leaflet of the plasma membrane
(39, 40, 41).
In vivo caspase-independent cell death may occur in physiological situations. This is the case for cell death of aging platelets, in which PS exposure has been reported (25). In vivo PS exposure during caspase-independent cell death as well as during apoptosis would guarantee the rapid recognition and engulfment of the dying cell, which is important to prevent inflammation and major damage to the organism. In contrast, during necrosis cells were neither exposed to PS nor phagocytosed before their death (42). In the latter situation engulfment of necrotic cells strongly stimulates the DC to mature and activate T cells, whereas recognition and engulfmemt of pure apoptotic cell populations by DC are nonstimulatory (4, 43).
Lastly, our results could have important consequences in attempts to manipulate apoptosis for therapeutic purposes. Indeed, in disorders characterized by excessive cell death, such as ischemia-reperfusion injury, neurodegenerative diseases, AIDS, or sepsis, preclinical studies with caspase inhibitors in animal models of human diseases have been reported (44). In most of these models caspase inhibitors decreased apoptosis and improved survival. However, caspase inhibitors may not completely prevent cell death, and their use carries the risk of transforming an apoptotic process into caspase-independent cell death, which may be potentially dangerous for the organism. Actually, our results demonstrate that, at least for primary T cells, PS exposure will not be affected by caspase inhibitors. The phagocytosis of dead cells will proceed normally and will prevent inflammation and damage to the organism.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 C.F.-P. and L.Q. contributed equally to this work and therefore share the first authorship. ![]()
3 Address correspondence and reprint requests to Dr. L. Genestier, Institut National de la Santé et de la Recherche Médicale, Unité 503, IFR74, Tour CERVI, 21 avenue Tony Garnier, 69365 Lyon Cedex 07, France. E-mail address: genestier{at}cervi-lyon.inserm.fr ![]()
4 Abbreviations used in this paper: PS, phosphatidylserine; AIF, apoptosis-inducing factor; DiOC6, 3,3'-dihexylocarbocyanine iodide; 
m, mitochondrial transmembrane potential; ETO, etoposide; PI, propidium iodide; STS, staurosporine; zIETD, Cbz-Ileu-Glu-Thr-Asp(OMe)-fluoromethylketone; zLEHD, Cbz-Leu-Glu-His-Asp(OMe)-fluoromethylketone; zVAD, Cbz-Val-Ala-Asp(OMe)-fluoromethylketone. ![]()
Received for publication July 26, 2002. Accepted for publication August 30, 2002.
| References |
|---|
|
|
|---|
. J. Biol. Chem. 275:23065.
-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol. 26:294.[Medline]
This article has been cited by other articles:
![]() |
N. Sasi, M. Hwang, J. Jaboin, I. Csiki, and B. Lu Regulated cell death pathways: New twists in modulation of BCL2 family function Mol. Cancer Ther., June 1, 2009; 8(6): 1421 - 1429. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tahvanainen, T. Kallonen, H. Lahteenmaki, K. M. Heiskanen, J. Westermarck, K. V. S. Rao, and R. Lahesmaa PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation Blood, February 5, 2009; 113(6): 1268 - 1277. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Dror, T. B. Kalynyak, Y. Bychkivska, M. H. Z. Frey, M. Tee, K. D. Jeffrey, V. Nguyen, D. S. Luciani, and J. D. Johnson Glucose and Endoplasmic Reticulum Calcium Channels Regulate HIF-1{beta} via Presenilin in Pancreatic {beta}-Cells J. Biol. Chem., April 11, 2008; 283(15): 9909 - 9916. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Mitchell, S. U. Morton, N. B. Fernhoff, and M. A. Marletta Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cells PNAS, July 10, 2007; 104(28): 11609 - 11614. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Elmore Apoptosis: A Review of Programmed Cell Death Toxicol Pathol, June 1, 2007; 35(4): 495 - 516. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Karmakar, R. D. Cummings, and R. P. McEver Contributions of Ca2+ to Galectin-1-induced Exposure of Phosphatidylserine on Activated Neutrophils J. Biol. Chem., August 5, 2005; 280(31): 28623 - 28631. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Nussbaum and J. L. Whitton The Contraction Phase of Virus-Specific CD8+ T Cells Is Unaffected by a Pan-Caspase Inhibitor J. Immunol., December 1, 2004; 173(11): 6611 - 6618. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ma, T. Greenwell-Wild, K. Lei, W. Jin, J. Swisher, N. Hardegen, C. T. Wild, and S. M. Wahl Secretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 Infection J. Exp. Med., November 15, 2004; 200(10): 1337 - 1346. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Huppertz and J. C. P. Kingdom Apoptosis in the Trophoblast--Role of Apoptosis in Placental Morphogenesis Reproductive Sciences, September 1, 2004; 11(6): 353 - 362. [Abstract] [PDF] |
||||
![]() |
B. S. Cummings, G. R. Kinsey, L. J. C. Bolchoz, and R. G. Schnellmann Identification of Caspase-Independent Apoptosis in Epithelial and Cancer Cells J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 126 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Michallet, F. Saltel, M. Flacher, J.-P. Revillard, and L. Genestier Cathepsin-Dependent Apoptosis Triggered by Supraoptimal Activation of T Lymphocytes: A Possible Mechanism of High Dose Tolerance J. Immunol., May 1, 2004; 172(9): 5405 - 5414. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Y. Tyurina, F. B. Serinkan, V. A. Tyurin, V. Kini, J. C. Yalowich, A. J. Schroit, B. Fadeel, and V. E. Kagan Lipid Antioxidant, Etoposide, Inhibits Phosphatidylserine Externalization and Macrophage Clearance of Apoptotic Cells by Preventing Phosphatidylserine Oxidation J. Biol. Chem., February 13, 2004; 279(7): 6056 - 6064. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Korfali, S. Ruchaud, D. Loegering, D. Bernard, C. Dingwall, S. H. Kaufmann, and W. C. Earnshaw Caspase-7 Gene Disruption Reveals an Involvement of the Enzyme during the Early Stages of Apoptosis J. Biol. Chem., January 9, 2004; 279(2): 1030 - 1039. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |